Business
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional Analyses
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional Analyses from SEQUOIA-HCM Assess Effect of Aficamten on Exercise Capacity and Dosing and Safety SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Clinical Trial presentations relating to SEQUOIA-HCM, (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), at Heart Failure 2024, an International Congress of the European Society of Cardiology, taking place in Lisbon, Portugal from May 11, 2024 – May 14, 2024. Title: Aficamten for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM an International Multicenter Phase 3 TrialPresenter: Martin Maron, M.D., Director, Hypertrophic Cardiomyopathy Center, Lahey Hospital and Medical CenterDate: May 13, 2024Topic: Heart Failure AssociationSession Title: Late Breaking Clinical Trials: LVAD, HFpEF and Hypertrophic CardiomyopathySession Type: Late Breaking ScienceSession Time: 1:45-2:45 PM WESTPresentation Time: 2:09 PM WESTLocation: Room 1 Title: Enhancing Exercise Response in Obstructive HCM: Insights from Aficamten's Impact on Patients with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM Presenter: Gregory Lewis, M.D., Jeffrey and Mary Ellen Jay Chair and Section Head, Heart Failure Medical Director, Cardiopulmonary Exercise Testing Laboratory, Professor of Medicine, Harvard Medical SchoolDate: May 13, 2024Topic: Heart Failure AssociationSession Title: Late Breaking Clinical Trials: LVAD, HFpEF and Hypertrophic CardiomyopathySession Type: Late Breaking ScienceSession Time: 1:45-2:45 PM WESTPresentation Time: 2:21 PM WESTLocation: Room 1 Title: Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCMPresenter: Caroline Coats, M.D., Ph.D., Lead Clinician, West of Scotland Inherited Cardiac Conditions Service, Honorary Senior Lecturer, School of Cardiovascular and Metabolic Health, University of GlasgowDate: May 13, 2024Topic: Heart Failure AssociationSession Title: Late Breaking Clinical Trials: LVAD, ...